These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27665680)

  • 1. A switching control law approach for cancer immunotherapy of an evolutionary tumor growth model.
    Doban AI; Lazar M
    Math Biosci; 2017 Feb; 284():40-50. PubMed ID: 27665680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of a cancer dormancy model and control of immuno-therapy.
    Sheller B; D'Alessandro D
    Math Biosci Eng; 2015 Oct; 12(5):1037-53. PubMed ID: 26280178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.
    de Pillis LG; Gu W; Radunskaya AE
    J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Clearance Analysis on a Cancer Chemo-Immunotherapy Mathematical Model.
    Valle PA; Coria LN; Salazar Y
    Bull Math Biol; 2019 Oct; 81(10):4144-4173. PubMed ID: 31264136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication?
    Krishchenko AP; Starkov KE
    Math Biosci Eng; 2018 Oct; 15(5):1243-1254. PubMed ID: 30380309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
    Castiglione F; Piccoli B
    Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells.
    Barbarossa MV; Kuttler C; Zinsl J
    Math Biosci Eng; 2012 Apr; 9(2):241-57. PubMed ID: 22901063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes.
    Chareyron S; Alamir M
    J Theor Biol; 2009 Jun; 258(3):444-54. PubMed ID: 18655792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of tumour-immune evasion with chemo-immuno therapeutic treatment with quadratic optimal control.
    Ravindran NS; Sheriff MM; Krishnapriya P
    J Biol Dyn; 2017 Dec; 11(1):480-503. PubMed ID: 28976297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dynamical model of tumour immunotherapy.
    Frascoli F; Kim PS; Hughes BD; Landman KA
    Math Biosci; 2014 Jul; 253():50-62. PubMed ID: 24759513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy.
    Wilkie KP
    Adv Exp Med Biol; 2013; 734():201-34. PubMed ID: 23143981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the Dichotomy of the Immune Response to Cancer: Cytotoxic Effects and Tumor-Promoting Inflammation.
    Wilkie KP; Hahnfeldt P
    Bull Math Biol; 2017 Jun; 79(6):1426-1448. PubMed ID: 28585066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues.
    Djema W; Bonnet C; Mazenc F; Clairambault J; Fridman E; Hirsch P; Delhommeau F
    J Theor Biol; 2018 Jul; 449():103-123. PubMed ID: 29678688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of immunotherapy.
    Disis ML
    Semin Oncol; 2014 Oct; 41 Suppl 5():S3-13. PubMed ID: 25438997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolutionary tradeoff and equilibrium in an aquatic predator-prey system.
    Jones LE; Ellner SP
    Bull Math Biol; 2004 Nov; 66(6):1547-73. PubMed ID: 15522345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stochastic eco-evolutionary model of a prey-predator community.
    Costa M; Hauzy C; Loeuille N; Méléard S
    J Math Biol; 2016 Feb; 72(3):573-622. PubMed ID: 26001744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies to improve tumor immunotherapy.
    Begley J; Ribas A
    Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunoediting: A process driven by metabolic competition as a predator-prey-shared resource type model.
    Kareva I; Berezovskaya F
    J Theor Biol; 2015 Sep; 380():463-72. PubMed ID: 26116366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of Tumor-Immune Coevolution on Cancer Evasion and Optimized Immunotherapy.
    George JT; Levine H
    Trends Cancer; 2021 Apr; 7(4):373-383. PubMed ID: 33446448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico tumor control induced via alternating immunostimulating and immunosuppressive phases.
    Reppas AI; Alfonso JC; Hatzikirou H
    Virulence; 2016; 7(2):174-86. PubMed ID: 26305801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.